ストックスクリーナーアプリを入手
0.2104
2.55%
-0.0053
前日終値:
$0.2157
開ける：
$0.2115
24時間の取引高:
11.50M
Relative Volume:
0.22
時価総額：
$19.86M
収益：
-
当期純損益:
$-21.91M
株価収益率:
-0.1412
EPS:
-1.49
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-4.45%
1か月 パフォーマンス:
+0.10%
6か月 パフォーマンス:
-90.08%
1年 パフォーマンス:
-92.87%
1日の値動き範囲:
$0.2049
$0.2199
1週間の範囲:
$0.2033
$0.227
52週間の値動き範囲:
$0.08
$3.1199
Incannex Healthcare Inc Stock (IXHL) Company Profile
名前
Incannex Healthcare Inc
セクター
電話
61 409 840 786
住所
8 CENTURY CIRCUIT, NORWEST NSW
IXHL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IXHL
Incannex Healthcare Inc
|
0.2104 | 19.86M | 0 | -21.91M | 0 | -1.49 |
|
RGC
Regencell Bioscience Holdings Ltd
|
15.16 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.28 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.37 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.41 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.68 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Incannex Healthcare Inc (IXHL) 最新ニュース
Incannex Flat on Looking Ahead to Clinical Trial - Baystreet.ca
Incannex Achieves Milestone in Sleep Apnea Drug Trial - TipRanks
Incannex completes database lock for sleep apnea drug trial - Investing.com
Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X - TradingView
Incannex forms joint venture with Mind Medicine Australia for clinic By Investing.com - Investing.com India
Incannex forms joint venture with Mind Medicine Australia for clinic - Investing.com
Incannex Healthcare Announces Psychedelic Therapies Joint Venture - TipRanks
Incannex Healthcare Forms Joint Venture With Mind Medicine Australia To Expand Access To Psychedelic-Assisted Therapy - MarketScreener
Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy - The Manila Times
Incannex Healthcare Inc. Forms Joint Venture with Mind Medicine Australia for Psychedelic-Assisted Therapy Clinic in Melbourne - Nasdaq
Groundbreaking Partnership: Incannex and Mind Medicine Launch Australia's Largest Psychedelic Therapy Center - Stock Titan
Incannex Healthcare Seeks Nasdaq Transfer to Meet Listing Rules By Investing.com - Investing.com Canada
Incannex Healthcare Seeks Nasdaq Transfer to Meet Listing Rules - Investing.com
Incannex Healthcare Transfers Listing to Nasdaq Capital Market - TipRanks
Incannex Healthcare Cancels Series A Warrants - TipRanks
Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution - The Manila Times
Incannex Cancels All Warrants, Removes 347M Share Dilution Before Critical Sleep Apnea Trial Data - Stock Titan
Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) - Revista ADVFN
Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates - mx.advfn.com
Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance - mx.advfn.com
Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules - mx.advfn.com
Incannex Expands Advisory Board for OSA Program - TipRanks
Incannex Healthcare Inc. Appoints Four Experts to IHL-42X Obstructive Sleep Apnea Clinical Advisory Board - Nasdaq
Harvard and Emory Leaders Join Incannex's Sleep Apnea Program Ahead of Critical Phase 2 Data - Stock Titan
Cannabis Stocks To Add to Your Watchlist – May 29th - Defense World
Incannex advances to phase 3 trial for sleep apnea treatment By Investing.com - Investing.com South Africa
Cannabis Stocks To ResearchMay 25th - MarketBeat
Cannabis Stocks To Consider – May 28th - Defense World
Incannex Healthcare Advances RePOSA Trial to Phase 3 - TipRanks
Incannex advances to phase 3 trial for sleep apnea treatment - Investing.com Australia
Incannex Healthcare Advances IHL-42X Reposa Trial To Phase 3 Following FDA Protocol Clearance - marketscreener.com
Breakthrough: FDA Green-Lights Phase 3 Trial for Revolutionary Oral Sleep Apnea Treatment - Stock Titan
Incannex cancels remaining Series A Warrants to reduce dilution By Investing.com - Investing.com South Africa
Promising Cannabis Stocks Worth Watching – May 27th - Defense World
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - BioSpace
Incannex Cancels Series A Warrants to Strengthen Capital - TipRanks
Incannex cancels remaining Series A Warrants to reduce dilution - Investing.com
Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results - The Manila Times
Incannex Cancels 347M Share Warrant Dilution Before Crucial Sleep Apnea Drug Data Release - Stock Titan
Incannex Healthcare Amends ATM Sales Agreement - TipRanks
SEC Form 424B5 filed by Incannex Healthcare Inc. - Quantisnow
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Cannabis Stocks To Research – May 25th - Defense World
Cannabis Stocks To Follow NowMay 24th - MarketBeat
Cannabis Stocks To Follow Now – May 24th - Defense World
Best Cannabis Stocks To Follow Now – May 23rd - Defense World
Top Cannabis Stocks To Keep An Eye On – May 22nd - Defense World
Best Cannabis Stocks To Watch TodayMay 18th - MarketBeat
Top Cannabis Stocks To Follow Now – May 20th - Defense World
Cannabis Stocks To Follow Today – May 19th - Defense World
Incannex's Big Leap Forward With Obstructive Sleep Apnea Study - Finimize
Incannex Healthcare Inc (IXHL) 財務データ
収益
当期純利益
現金流量
EPS
1.37%
0.60%
大文字化:
|
ボリューム (24 時間):